GreenGro Technologies, Inc.(GRNH), a world-class provider of eco-friendly green technologies, today announced the launch of its newly formed CBD Subsidiary, EMS Meds, Inc., which will focus on the research and development of a full line of premium CBD products that will be distributed directly to doctors’ offices, medical facilities and specialty retailers.
Today’s announcement is a result of the GreenGro’s formation of EMS Meds, Inc. (www.educationalmarijuanasciences.com), to develop new and innovative medicines and treatments that are derived from CBD, the non-psychoactive component in cannabis that is known for its health and wellness benefits. As part of the strategic alliance, Dr. Mark Wagner, Founder and CEO of EMS Meds, Inc. has been appointed to the Board of Directors of GreenGro Technologies.
EMS Meds will serve as the GreenGro’s clinical arm dedicated to the production of CBD-based medicines and treatments. GreenGro noted that its targeted distribution network, which should be covered by most insurance carriers, will make its CBD products available to a large number of patients who until today could not afford CBD-derived medications.
“The CBD market is growing everyday as more and more consumers are learning how powerful CBD can be as an all-natural alternative to opioids, and can be a natural remedy for such ailments as asthma, insomnia, anxiety, depression, arthritis, among others,” said James Haas, Chairman and CEO of GreenGro Technologies, Inc. “Our entry into this significant market was a natural next step for our company as we strive to add new revenue streams to our business model and focus on enhancing shareholder value,” concluded Mr. Haas.
Company Adds CBD Pioneer to Board of Directors
As part of the Company’s strategic alliance with EMS Meds, Inc., its Founder and CEO, Dr. Mark Wagner, has been added to the Company’s Board of Directors. Dr. Wagner currently also serves as the Director of OC Comprehensive Care in Santa Ana. He graduated Phi Beta Kappa from the University of California, Irvine with degrees in Biology and Chemistry prior to attending UCLA School of Medicine. After completing an Emergency Medicine Residency at Harbor UCLA, he practiced Emergency Medicine for 30 years throughout Los Angeles and Orange County. Dr. Wagner is an advocate for the indigent and underinsured and served as an independent appeals and grievance consultant for a major health insurance plan in the past. At OC Comprehensive Care, Dr. Wagner and his associates specialize in treating patients who are very commonly ignored by their primary providers due to chronic pain, anxiety, depression, mood disorders, ADD/ADHD, PTSD, or other poorly understood conditions. Dr. Wagner has researched the benefits of medicinal hemp and cannabis and consults patients on individualizing their treatment plan utilizing hemp and cannabis to reduce the burden of controlled substances and psychotropic pharmaceuticals that have recognized and sometimes dangerous and lethal consequences. By joining GreenGro Technologies, Dr. Wagner will have the ability to research, develop, and market quality branded medicinal hemp and cannabis products.
The Multi-Billion Dollar and Growing Cannabidiol (CBD) Market
CBD is a non-psychoactive cannabinoid proving to be useful as an anti-inflammatory, antioxidant and neuroprotectant. As such, CBD is being used in the treatment of a number of conditions including cancer, pain and inflammation and GI tract issues, among others. As researchers and institutions have developed a better understanding of its positive impacts, there have been regulatory changes aimed at breaking down the entry barriers into the CBD market. One notable instance of this is the recent announcementfrom the World Anti-Doping Agency (WADA) in which the organization removed CBD from its prohibited substances list. Its reasoning is that CBD does not mimic the effects of tetrahydrocannabinol (THC)—the psychoactive component of cannabis.
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers